Boston Scientific Amount that if recognized, would affect the effective tax rate or regulatory liability decreased by 0.7% to $444.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 6.5%, from $417.00M to $444.00M. Over 4 years (FY 2020 to FY 2024), Amount that if recognized, would affect the effective tax rate or regulatory liability shows an upward trend with a 23.3% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A high value indicates significant potential volatility in the effective tax rate based on future tax authority rulings.
This represents the portion of unrecognized tax benefits that, if recognized, would directly impact the company's effect...
Standard disclosure for public companies; utility peers typically maintain low levels due to the regulated nature of their tax recovery.
other_unrecognized_tax_benefits_that_would_impact_effect_ff36cb| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $195.00M | $195.00M | $177.00M | $183.00M | $333.00M | $340.00M | $410.00M | $415.00M | $406.00M | $419.00M | $395.00M | $393.00M | $406.00M | $417.00M | $423.00M | $431.00M | $447.00M | $444.00M |
| QoQ Change | — | +0.0% | -9.2% | +3.4% | +82.0% | +2.1% | +20.6% | +1.2% | -2.2% | +3.2% | -5.7% | -0.5% | +3.3% | +2.7% | +1.4% | +1.9% | +3.7% | -0.7% |
| YoY Change | — | — | — | — | +70.8% | +74.4% | +131.6% | +126.8% | +21.9% | +23.2% | -3.7% | -5.3% | +0.0% | -0.5% | +7.1% | +9.7% | +10.1% | +6.5% |